<DOC>
	<DOCNO>NCT00341705</DOCNO>
	<brief_summary>The Second Multicenter Hemophilia Cohort Study ( MHCS-II ) evaluate prospectively follow approximately 4500 person hemophilia expose hepatitis C virus ( HCV ) . The vast majority infect HCV , approximately 1/3 infected human immunodeficiency virus ( HIV ) . Primary objective quantify rate liver decompensation , hepatocellular carcinoma , non-Hodgkin lymphoma evaluate candidate clinical , genetic , virologic , serologic immunologic marker likely causal pathway condition . Candidate clinical laboratory marker examine longitudinally define change time relationships one another . Collaborative study focus genome scan evaluation candidate genetic locus susceptibility resistance HCV HIV infection diseases result infection . Additional study identify response complication rate various anti-HCV anti-HIV regimen set comprehensive clinical care person hemophilia .</brief_summary>
	<brief_title>The Second Multicenter Hemophilia Cohort Study</brief_title>
	<detailed_description>The Second Multicenter Hemophilia Cohort Study ( MHCS-II ) evaluate prospectively follow approximately 4500 person hemophilia expose hepatitis C virus ( HCV ) . The vast majority infect HCV , approximately 1/3 infected human immunodeficiency virus ( HIV ) . Primary objective quantify rate liver decompensation , hepatocellular carcinoma , non-Hodgkin lymphoma evaluate candidate clinical , genetic , virologic , serologic immunologic marker likely causal pathway condition . Candidate clinical laboratory marker examine longitudinally define change time relationships one another . Collaborative study focus genome scan evaluation candidate genetic locus susceptibility resistance HCV HIV infection diseases result infection . Additional study identify response complication rate various anti-HCV anti-HIV regimen set comprehensive clinical care person hemophilia .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<criteria>INCLUSION CRITERIA : Must register patient inherit coagulation disorder participate MHCSII center . Disorders include hemophilia A B ( congenital factor VIII IX deficiency ) , deficiencies factor V XI , vonWillebrand 's disease . ( Unless note otherwise , disorder collectively refer hemophilia . ) All hemophilia vonWillebrand disease patient recruit study participant . Since January 1 , 1993 , must least one positive result license assay HCV antibody , HIV antibody , HIV RNA . Must least 13 year age enrollment . Must provide sign informed consent , minor , sign assent plus sign inform consent parent guardian . EXCLUSION CRITERIA : Is patient inherited coagulation disorder . Does positive test HCV antibody , HIV antibody , HIV RNA license assay perform since January 1 , 1993 . Is less 13 year age . Lacks inform consent/assent .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2, 2013</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>HIV</keyword>
	<keyword>Natural History</keyword>
	<keyword>Hemophilia</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>